Sangeetha Venugopal - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Sangeetha Venugopal

Showing results (31-40 of 35) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 35 results.

Blood Advances|November 2, 2022

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLGhayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.

JCO Oncology Practice|July 16, 2024

Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisFadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.

Blood Advances|August 16, 2022

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeCourtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.

Blood Neoplasia|June 2, 2025

Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemiaEllen Madarang, Jillian Lykon, Wei Zhao, et al.

Haematologica|February 26, 2026

Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapyJustin Watts, Ellen Madarang, Diana Abbott, et al.

Pageof 4

Search research articles

Showing results (31-40 of 35) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 35 results.

Blood Advances|November 2, 2022

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLGhayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.

JCO Oncology Practice|July 16, 2024

Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisFadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.

Blood Advances|August 16, 2022

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeCourtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.

Blood Neoplasia|June 2, 2025

Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemiaEllen Madarang, Jillian Lykon, Wei Zhao, et al.

Haematologica|February 26, 2026

Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapyJustin Watts, Ellen Madarang, Diana Abbott, et al.

Pageof 4